Figure 1. Application of contrast echocardiography in patients with systemic hypertension and hypertensive heart disease.
| Cardiology Research, ISSN 1923-2829 print, 1923-2837 online, Open Access |
| Article copyright, the authors; Journal compilation copyright, Cardiol Res and Elmer Press Inc |
| Journal website https://www.cardiologyres.org |
Review
Volume 2, Number 6, December 2011, pages 259-268
Myocardial Contrast Echocardiography in the Evaluation of Hypertensive Heart Disease
Figure
Table
| Name | Gas | Mean diameter (Micro meters) | Concentration .ml-1 | Comments |
|---|---|---|---|---|
| FDA: Food and Drug Administration. | ||||
| Levovist | Air | 1.2 | 1.2-2.0 .108 | Available in many countries but not in USA |
| Albunex | Air | 4.3 | 0.5 .109 | For LV opacification |
| Imagent | Perfluorohexane | 5.0 | 0.5 .108 | For LV opacification |
| Optison | Perflutren | 3.0-4.5 | 5.0-8.0 .108 | Available in USA and Europe for LV opacification |
| Sonazoid | Perflubutane | 2.4-2.5 | 0.3 .109 | Available in Japan for Liver opacification |
| Definity | Octafluropropane | 1.1-3.3 | 1.2 .1010 | Available in USA, Europe for LV opacification |
| Sonovue | Sulphur hexafluoride | 2.5 | 5.0 .108 | Available in Europe for LV Opacification |
| Cardiosphere | Nitrogen | 3.0 | 2.0 - 5.0 .108 | Under FDA review for MCE |
| Imagify | Decafluorobutane | 2.3 | Gas 260 ± 25 micro g.ml-1 of reconstituted produc | Under FDA review for MCE |